Please help spread the word for the final time by reposting the above:
@ishahjain.bsky.social @bradylabupenn.bsky.social @naama-kanarek.bsky.social @liron1bar-peled.bsky.social @lydiafinley.bsky.social

Hot off the presses! Was an honor to team up with Scott Dixon @stanforduniversity.bsky.social on this Nature Cancer review. We reflect on hurdles that have slowed translation of ferroptosis-directed therapies and share ideas on what it will take to bring these therapies to the clinic. rdcu.be/eBbqV

please repost and share with your followers: @ishahjain.bsky.social @bradylabupenn.bsky.social @naama-kanarek.bsky.social @liron1bar-peled.bsky.social @lydiafinley.bsky.social

Honored to receive @bwfund.bsky.social Career Award for my research on #mitochondria #peroxisomes and be 1st neonatologist awardee! The $700K for starting my lab will enable exciting research on #organelles #metabolism to help medicine’s smallest patients. #neonatal www.bwfund.org/news/bwf-ann...

please repost @ishahjain.bsky.social @bradylabupenn.bsky.social @naama-kanarek.bsky.social @liron1bar-peled.bsky.social @lydiafinley.bsky.social

Last night, past Mark Foundation Emerging Leader Award winners gathered with this year’s recipients, @marasherman.bsky.social , @liron1bar-peled.bsky.social, Kai Kessenbrock, Ansu Satpathy, and Dan Wahl, to celebrate seven years of this transformational program. #MarkSymposium

I’m excited to share the latest work from our lab, led by a group of three amazing scientists: Junbing Zhang, Yousuf Ali and Harrison Chong, who describe @nature the discovery of a ROS sensor, VPS35, which links cytosolic H2O2 levels to regulation of mitochondrial translation and

Today in @nature.com we share our back-to-back stories with Ning Zheng’s lab revealing chemical-genetic convergence between a molecular glue degrader & E3 ligase cancer mutations. 1/5

Excited to share our new study on translocation RCC (tRCC) in collaboration with @liron1bar-peled.bsky.social. We reveal how the TFE3 fusion drives a key oxidative phosphorylation (OXPHOS) metabolic program in this rare kidney cancer. trebuchet.public.springernature.app/get_content/... 1/

@liron1bar-peled.bsky.social will use his ELA to develop "molecular staples," a new class of drugs designed to disrupt oncogenic fusion proteins, which form when two genes abnormally join together and can drive many different types of cancers. @massgeneralbrigham.bsky.social

We’ve preprinted a small follow-up to our identification of MFSD12 as a mediator of lysosomal cysteine import. Would love to discuss, so please get in contact if you have comments or suggestions!

🧪 Ready, set, degrade!

So proud to share our work in the @jclinical-invest.bsky.social, establishing a versatile approach for creating transgenic dTAG mice to degrade oncoproteins. We showcase that KRAS G12V degradation triggers antitumor immunity in lung cancer.

Link: www.jci.org/articles/vie...

We are moving one step closer to our goal to develop a general method to red-shift photoswitchable ligands as a foundation for in vivo photopharmacology with our latest work: "A platform for the development of highly red-shifted azobenzenes". Link: doi.org/10.26434/che....

“NIH produces an astounding return on investment to the American taxpayer. In Fiscal Year 2022, NIH research funding supported 568,585 jobs and generated $96.84 billion in economic activity — that’s $2.64 of economic activity for every $1 of research funding.”
www.researchamerica.org/2023-oped-us...

Like ‘old Twitter’: The scientific community finds a new home on Bluesky

another incredible piece of news!

www.science.org/content/arti...